Sensory Characteristics and Psychosocial Factors Related With Non-specific Neck Musculoskeletal Pain Chronification (CNSNP)
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Contactos e Locais
Locais de estudo
-
-
-
Zaragoza, Espanha, 50009
- Hospital General de la Defensa
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion criteria for individuals with CNSNP were:
- age between 18 and 65 years;
- capable to understand, write, and speak in Spanish;
- having suffered neck pain during the last 12 weeks at least;
- pain localized in the neck region with or without pain radiation;
- Negative Spurling test;
- Negative Self-Administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS);
- Negative Upper Limb Tension Test for the median nerve;
- PainDetect test with non-neuropathic pain result. .
Exclusion Criteria:
- Presence of red flag as reported in the medical history (i.e. tumor, fracture, metabolic diseases, rheumatoid arthritis, osteoporosis);
- Neck pain with cervical radiculopathy;
- fibromyalgia syndrome,
- previous neck surgery;
- currently undergoing any type of pain treatment or having received physical therapy in the previous 3 months.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Chronic Non-Specific Neck Pain
Patients with chronic non-specific neck pain.
No interventions
|
Observational study
|
|
Control/Healthy Group
Volunteers without pain.
No interventions.
|
Observational study
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Neck Disability Index Change
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
It is a 10-item questionnaire that measures a patient's self-reported neck pain related disability.
Questions include activities of daily living, such as: personal care, lifting, reading, work, driving, sleeping, recreational activities, pain intensity, concentration and headache.
The 10 item scores are then summed to yield a global NDI score, which has a range of 0-50 where higher values reflect greater neck disability. 1 and 6-month results were subtracted from baseline.
As such, positive change scores for neck disability indicate improvement
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Quick-DASH change
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
The purpose of the QuickDASH is to use 11 items to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb.
The QuickDASH is a widely used reference of self reported disability.
The 11 item scores are then summed to yield a global QuickDASH score, which has a range of 11-100 where higher values reflect greater shoulder/arm disability. 1 and 6-month results were subtracted from baseline.
As such, positive change scores for shoulder/arm disability indicate improvement
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pressure Pain Threshold change
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
Pressure pain threshold (PPT) is defined as the minimum force applied which induces pain.
This measure has proven to be commonly useful in evaluating tenderness symptom.
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Temporal Summation change
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
Temporal summation is a clinical measure of central sensitization in which a high frequency of action potentials in the presynaptic neuron elicits postsynaptic potentials that overlap and summate with each other.
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Area of pain assessed by bodycharts change
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
Participants have to draw on a tablet-based digital body chart (NavigatePain©, Aalborg University, Aalborg, Denmark) the body region in which they felt pain more frequently during the previous month.
The use of pain drawings has been found to be reliable in chronic low back, neck, shoulder, and arm pain.
Digital pain drawings have also been shown reliable, valid and comparable to paper drawings and useful in clinical population.
The size of the pain area was extracted and expressed in pixels.
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Pain Intensity change- Visual Analogic Scale
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
Self-perceived neck pain will record using a Visual Analogue Scale (VAS).
Participants have to mark on a 10-cm line their average current neck pain between 0 ("no pain") and 10 ("worst possible pain").
The VAS is a reliable and valid measurement of pain
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Pain Duration change
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
Duration of pain in months
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Catastrophism change. Pain Catastrophizing Scale
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
People are asked to indicate the degree to which they have the above thoughts and feelings when they are experiencing pain using the 0 (not at all) to 4 (all the time) scale.
A total score is yielded (ranging from 0-52), along with three subscale scores assessing rumination, magnification and helplessness.
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Kinesiophobia change. Tampa Scale for Kinesiophobia
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
Tampa Scale for Kinesiophobia (TSK) The TSK is a 17-item self-report measure of fear of movement and (re)injury.
Four of the items are negatively worded and reversed scored (4, 8, 12, and 16).
Ratings are summed to yield a total score where higher values reflect greater fear of (re)injury.
The 17 item scores are then summed to yield a global TSK score, which has a range of 11-44.
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Quality of Life change. The 5-level EQ-5D version (EQ-5D-5L)
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
The EQ-5D is a frequently used generic quality of life questionnaire, designed by the EuroQoL.
The EQ-5D-5L is an instrument widely used to measure and evaluate general health status.
The EQ-5D-5L descriptive system describes general health in terms of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has five levels, indicating no problems, slight problems, moderate problems, severe problems, and extreme problems resulting in a total of 3,125 unique health states.
Besides, the EQ-5D-5L also includes a visual analogue scale (EQ-VAS), which recorded the patient's self-rated health on a 20 cm vertical, visual analogue scale with endpoints (0; 100) labeled 'the best health you can imagine' and 'the worst health you can imagine'
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Stress change. Perceived Stress Scale
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
he Perceived Stress Scale (PSS) inquire about feelings and thoughts that tap the degree to which respondents find their current life situation unpredictable, uncontrollable and stressful.
Respondents indicate how often in the past month they have felt or thought a certain way on a 5-point Likert scale (0 = never, 1 = almost never, 2 = sometimes, 3 = fairly often, 4 = very often).
The higher the score the higher the perceived stress is.
The 14 item scores are then summed to yield a global PSS score, which has a range of 0-56
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Quality of Sleep change . Pittsburgh Questionnaire
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
PSQI consists of 19 self-rated questions.
The 19 self-rated questions asses a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep-related problems.
Theses 19 items are grouped into seven component scores, each weighted equally on a 0-3 scale.
The seven component scores are then summed to yield a global PSQI score, which has a range of 0-21; higher scores indicate worse sleep quality.
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
|
Anxiety-Depression change. DASS 21.
Prazo: T0 (baseline); T1 (1 month); T2 (6 months).
|
The DASS is a self-report measure, designed to assess the unique and unrelated aspects of anxiety and depression, as well as a third construct (termed stress) that assesses the features common to anxiety and depression.
The DASS-21 is comprised of three scales, Depression, Anxiety, and Stress, each of which consists of 7 items.
The 21 item scores are then summed to yield a global DASS-21 score, which has a range of 0-63
|
T0 (baseline); T1 (1 month); T2 (6 months).
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- CNSNP-USJ
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .